Skip to main content

Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO

ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.